Toll-like receptor 4

Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)

Retrieved on: 
Wednesday, March 13, 2024
Health, Infectious Diseases, Surgery, General Health, Clinical Trials, Pharmaceutical, Biotechnology, CRRT, Conference, Rat, Disease, AKI, TLR4, Acute kidney injury, Immunity, Toll-like receptor 4, Poster, Animal, Kidney

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI.

Key Points: 
  • Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI.
  • A copy of the presentation and poster presented at the AKI and CRRT 2024 Conference can be found on Revelation’s website .
  • In addition to clinical observation, rats were evaluated for markers of kidney function at 24 and/or 72 hours post-surgery, and markers of kidney damage at 72 hours post-surgery.
  • Reduced overall damage (necrosis) of the cortical (p

TRS01 for Autoimmune Uveitis in Seven Major Markets: Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024
Health, Pharmaceutical, Toll-like receptor 4, Uveitis, SWOT, EU4, TRS, Autoimmunity, TLR4, Research, Immune system, Pharmaceutical industry

This report provides comprehensive insights about TRS01 for autoimmune uveitis in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about TRS01 for autoimmune uveitis in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the TRS01 market forecast analysis for autoimmune uveitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in autoimmune uveitis.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRS01 in autoimmune uveitis.
  • The report also features the SWOT analysis with analyst views for TRS01 in autoimmune uveitis.

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Retrieved on: 
Monday, March 4, 2024
Health, Infectious Diseases, Surgery, Clinical Trials, Research, Science, Biotechnology, Diabetes, Incidence, Toll-like receptor 4, Fungal infection, Gemini, Infection, Safety, Biomarker, Ischemia, Acute kidney injury, Patient, AKI, Disease, Immunity, Trial of the century, TLR4, Genetically modified bacteria, Pharmaceutical industry

The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.

Key Points: 
  • The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of age.
  • Data from this Phase 1 clinical study will support future development across multiple indications.
  • Preclinical studies using models of AKI have demonstrated pretreatment with Gemini can reduce the severity and duration of AKI.
  • The start of this study is an important step toward bringing a potential new therapy for these unmet needs.”

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

Retrieved on: 
Tuesday, January 30, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Senior, CRRT, AKI, Acute kidney injury, Toll-like receptor 4, TLR4, Conference

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024).

Key Points: 
  • Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024).
  • Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI and hospital acquired infection.
  • Robin Marsden, Senior Vice President of Biology, Revelation Biosciences
    “We are delighted to have the opportunity to present our exciting preclinical data for the prevention of acute kidney injury (AKI),” said James Rolke, Chief Executive Officer of Revelation.
  • “We are grateful to the conference organizers for creating a forum for industry, academia, and key opinion leaders to share data and ideas in this critical area of medicine.”